Glenmark Pharmaceuticals Ltd., a research-driven global pharmaceutical company, has expanded its cardiometabolic portfolio in India with the launch of Empagliflozin and its fixed-dose combinations (FDCs) under the brand names Glempa, Glempa-L, and Glempa-M. The move aims to provide effective treatment solutions for type 2 diabetes mellitus (T2DM) while addressing cardiovascular risks.
Empagliflozin, a widely recognized SGLT2 inhibitor, has been shown to improve glycemic control, support weight loss, and reduce cardiovascular-renal risks in T2DM patients. Clinical studies highlight its benefits, including a 14% reduction in major cardiovascular events as per the EMPA-REG trial. The new Glempa range offers multiple treatment options: Glempa (Empagliflozin 10/25 mg), Glempa-L (Empagliflozin + Linagliptin), and Glempa-M (Empagliflozin + Metformin).
Alok Malik, President and Head of India Formulations Business at Glenmark, stated, “With a strong legacy in cardiometabolic care, Glenmark’s Glempa range provides an affordable and comprehensive solution to better manage T2DM and its associated cardiovascular risks.” With Kolkata emerging as a key healthcare hub, the launch of the Glempa range is expected to boost accessibility to advanced diabetes care in the region. Pharmacists and healthcare providers in the city anticipate strong demand for the new medications, given the rising prevalence of diabetes and cardiovascular diseases. Experts believe the affordability and efficacy of Glenmark’s offerings will enhance treatment adherence among patients in Kolkata and neighboring markets.